A phase III/IV randomised open-label study and comparison of the immunogenicity and safety of a single adolescent booster dose of a meningococcal group C conjugate-containing booster vaccine (Meningitec, or Menjugate, or NeisVac-C, or Menitorix), when given concurrently with an acellular pertussis-containing booster vaccine (Repevax or IPV-Boostrix)

Trial Profile

A phase III/IV randomised open-label study and comparison of the immunogenicity and safety of a single adolescent booster dose of a meningococcal group C conjugate-containing booster vaccine (Meningitec, or Menjugate, or NeisVac-C, or Menitorix), when given concurrently with an acellular pertussis-containing booster vaccine (Repevax or IPV-Boostrix)

Completed
Phase of Trial: Phase III/IV

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs Meningococcal vaccine group C conjugate (Primary) ; DTaP poliovirus vaccine; Hib-meningococcal vaccine group C conjugate
  • Indications Diphtheria; Haemophilus infections; Meningococcal group C infections; Pertussis; Poliomyelitis; Tetanus
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms Multiboost
  • Most Recent Events

    • 05 Apr 2017 Status changed from recruiting to completed.
    • 31 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Mar 2017.
    • 31 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Mar 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top